Dr. Yongqing Li 李永清
Chief Physician
Department of Breast Surgery II, Cancer Hospital of Shandong First Medical University (Shandong Cancer Hospital), Jinan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Breast-conserving surgery, modified radical mastectomy, sentinel lymph node biopsy, minimally invasive mammotome excision, and endoscopic breast cancer surgery. Provides individualized chemotherapy, endocrine therapy, and targeted therapy for early to late-stage breast cancer.
Dr. Li is Chief Physician and Head of the Second Breast Surgery Ward at Shandong Cancer Hospital. Holding a master’s degree in surgery, Dr. Li has specialized in breast disease diagnosis and treatment since 2000. A member of the hospital’s breast cancer MDT team, Dr. Li has co-authored several books and published over 10 papers.
Professional roles
- Standing Committee Member, Breast Tumor Branch, Shandong Anti-Cancer Association
- Vice Chair, Youth Committee of Breast Tumor Branch, Shandong Anti-Cancer Association
- Editorial Board Member, Chinese Journal of Oncology (8th Edition)
- Member, Breast Disease Branch, China International Exchange and Promotive Association for Medical and Health Care
Name order: in Chinese the family name comes first (Li Yongqing). Papers usually list the name as Yongqing Li or Li Y.
Selected publications
19 papers on PubMed matched by name and affiliation; 4 as first or senior author since 2016. Most recent first- or senior-author papers:
- ACS Omega, 2024 (first author): TMEM147: A Promising Cancer Biomarker Associated with Immune Cell Infiltration and Prognosis in LIHC-Insights from a Comprehensive Pan-Cancer Genomic Analysis. PubMed 38947838
- Nutr Metab (Lond), 2023 (first author): METTL3 exacerbates insulin resistance in hepatocytes by regulating m(6)A modification of cytochrome P450 2B6. PubMed 37710320
- J Cancer Res Ther, 2022 (first author): Meta-analysis of the efficacy of glycyrrhizin for postoperative liver preservation in patients with liver cancer. PubMed 35645115
- Biomed Pharmacother, 2019 (senior author): Improving breast cancer therapy using doxorubicin loaded solid lipid nanoparticles: Synthesis of a novel arginine-glycine-aspartic tripeptide conjugated, pH sensitive lipid and evaluation of the nanomedicine in vitro and in vivo. PubMed 31152925
- Cancer Biomark, 2015 (first author): Associations of miR-146a and miR-146b expression and breast cancer in very young women. PubMed 26406414
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion